| pubmed-article:10513354 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10513354 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10513354 | lifeskim:mentions | umls-concept:C0004096 | lld:lifeskim |
| pubmed-article:10513354 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:10513354 | lifeskim:mentions | umls-concept:C0700624 | lld:lifeskim |
| pubmed-article:10513354 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:10513354 | lifeskim:mentions | umls-concept:C0117996 | lld:lifeskim |
| pubmed-article:10513354 | lifeskim:mentions | umls-concept:C1819433 | lld:lifeskim |
| pubmed-article:10513354 | lifeskim:mentions | umls-concept:C0392760 | lld:lifeskim |
| pubmed-article:10513354 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10513354 | pubmed:dateCreated | 1999-11-9 | lld:pubmed |
| pubmed-article:10513354 | pubmed:abstractText | Fluticasone propionate is a very effective topical treatment for asthma. Interleukin-12, which is produced by monocyte-macrophage and B lymphocytic cell lines, plays an important role in the induction of Th1 cells; whereas interferon-gamma (IFN-gamma), mainly produced by Th1 cells, exhibits a crucial effect on macrophage and natural killer cell activation. Since previous studies have demonstrated a reduced production of IL-12 and IFN-gamma in patients with allergic asthma, we examined whether fluticasone propionate therapy could influence the release of these cytokines in asthma. We selected two groups of subjects (15 per group): nonatopic healthy donors (group A) and asthmatic patients (group B). Cytokine release was assessed in sera as well as in supernatants of whole blood cultures after IFN-gamma priming and lipopolysaccharide stimulation. Venous blood and spirometric tests from patients in group B were obtained before and after treatment. Fluticasone propionate therapy significantly increased interleukin-12 levels in both supernatants of blood cultures (1,152.12 +/- 225.57 vs. 540.87 +/- 130.07 pg/ml; p < 0.05) or in sera (72.24 +/- 15.76 vs. 10.83 +/- 2.70 pg/ml; p < 0.05). Patients treated with fluticasone propionate also displayed increased levels of IFN-gamma in either blood culture supernatants (59.12 +/- 16.88 vs. 18.87 +/- 7.53 IU/ml; p < 0.05) or in sera (5.60 +/- 2.87 vs. < 1 IU/ml; p < 0.05). In addition, we observed a significant increase in FEV1 values in asthmatic patients after fluticasone propionate therapy (51.86 +/- 5.31 vs. 71.46 +/- 10.37% predicted). We propose that fluticasone propionate may exert at least in part of its antiinflammatory activity through the modulation of the cytokine output. | lld:pubmed |
| pubmed-article:10513354 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10513354 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10513354 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10513354 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10513354 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10513354 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10513354 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10513354 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10513354 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10513354 | pubmed:issn | 1018-9068 | lld:pubmed |
| pubmed-article:10513354 | pubmed:author | pubmed-author:RicciardiLL | lld:pubmed |
| pubmed-article:10513354 | pubmed:author | pubmed-author:ArenaAA | lld:pubmed |
| pubmed-article:10513354 | pubmed:author | pubmed-author:MerendinoR... | lld:pubmed |
| pubmed-article:10513354 | pubmed:author | pubmed-author:GangemiSS | lld:pubmed |
| pubmed-article:10513354 | pubmed:author | pubmed-author:GuarneriFF | lld:pubmed |
| pubmed-article:10513354 | pubmed:author | pubmed-author:Purello-D'Amb... | lld:pubmed |
| pubmed-article:10513354 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10513354 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:10513354 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10513354 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10513354 | pubmed:pagination | 262-7 | lld:pubmed |
| pubmed-article:10513354 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:meshHeading | pubmed-meshheading:10513354... | lld:pubmed |
| pubmed-article:10513354 | pubmed:articleTitle | Effect of fluticasone propionate on interleukin-12 and interferon-gamma production in patients affected by allergic bronchial asthma. | lld:pubmed |
| pubmed-article:10513354 | pubmed:affiliation | School of Allergology and Clinical Immunology, Policlinic G. Martino, University of Messina, Medical School, Italy. | lld:pubmed |
| pubmed-article:10513354 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10513354 | pubmed:publicationType | Clinical Trial | lld:pubmed |
